Novavax (NASDAQ: NVAX  ) is about to take an injection of fresh capital. The company is floating just under 27.7 million shares of its common stock in an underwritten public offeringpriced at $3.14 per share. Additionally, the issue's underwriters have been granted a 30-day purchase option for up to an additional 4,153,950 shares to cover overallotments.

Novavax said it plans to use the offering's anticipated net proceeds of roughly $82.6 million for "general corporate purposes, the advancement of its clinical-stage vaccine candidates and its pre-clinical research programs."

Lazard Capital Markets is the sole book-running manager of the issue, which is expected to close on or about this Friday.
Currently, Novavax has nearly 152.7 million shares outstanding, and its stock most recently closed at $3.21 per share.

Even More Premium Stock Picks

Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.